Yeadon M, Dougan F L, Petrovic A, Beesley J E, Payne A N
Department of Pharmacology, Wellcome Research Laboratories, Beckenham, Kent, UK.
Agents Actions. 1993 Jan;38(1-2):8-18. doi: 10.1007/BF02027207.
The actions of BW B70C, an orally available, biologically persistent and selective inhibitor of arachidonic acid 5-lipoxygenase, have been examined in two systems of anaphylaxis in actively sensitised guinea-pigs in vivo. In anaesthetised, artificially ventilated animals pretreated with mepyramine and indomethacin to leave only the "peptidoleukotriene-dependent" component (leukotrienes C4, D4 and E4) of the anaphylactic response, direct inhalation of nebulised allergen resulted in a slowly developing bronchoconstriction which was prevented in a dose-dependent manner by BW B70C (2-50 mg/kg p.o.) administered 1 or 6 h before challenge. In conscious animals fasted overnight and then pretreated with mepyramine to prevent death due to acute bronchial anaphylaxis, exposure to nebulised allergen produced slight respiratory symptoms. When blood and lung samples were analysed 4-48 h after allergen provocation a sustained leukocytosis and pulmonary eosinophil accumulation were observed. In contrast, in food-replete conscious animals, the early respiratory symptoms were still observed upon allergen inhalation, but no significant blood leukocytosis or accumulation of eosinophils in the lungs occurred subsequently. The eosinophil influx induced by allergen in fasted animals was assessed both by histological examination and determination of tissue peroxidase content, two measures which demonstrated reasonable agreement. Administration of a single dose of BW B70C (10 mg/kg p.o.) 1 h prior to allergen challenge did not affect the subsequent eosinophil infiltration 24 h later, but 20 mg/kg given in divided doses (-1 and +12 h) produced 67% inhibition of cell accumulation. A single dose of 50 mg/kg (-1 h) had a similar effect (78% inhibition). The potent glucocorticosteroid betamethasone was used as a reference compound, and 4 mg/kg given as a divided dose (-1 and +7) fully inhibited lung inflammation assessed 24 h after provocation with allergen. BW B70C inhibited both acute and allergic bronchoconstriction and late-phase eosinophil accumulation subsequent to allergen inhalation in guinea-pigs. In view of the apparent requirement for sustained plasma levels of BW B70C in order to prevent late-phase eosinophil recruitment to the lung after a single challenge with allergen, it is unclear whether inhibition of 5-lipoxygenase underlies the observed anti-eosinophil accumulation effects of the compound, but the anti-bronchoconstrictor effects are consistent with the known inhibitory activity of BW B70C against 5-lipoxygenase.
BW B70C是一种口服有效的、具有生物持久性且选择性的花生四烯酸5-脂氧合酶抑制剂,其作用已在两个主动致敏豚鼠体内过敏反应系统中进行了研究。在预先用美吡拉敏和吲哚美辛处理以仅保留过敏反应中“肽白三烯依赖性”成分(白三烯C4、D4和E4)的麻醉、人工通气动物中,直接吸入雾化变应原会导致缓慢发展的支气管收缩,而在激发前1或6小时口服给予BW B70C(2 - 50 mg/kg)可呈剂量依赖性地预防这种收缩。在禁食过夜然后用美吡拉敏预处理以防止因急性支气管过敏反应而死亡的清醒动物中,暴露于雾化变应原会产生轻微的呼吸道症状。在变应原激发后4 - 48小时分析血液和肺样本时,观察到持续的白细胞增多和肺嗜酸性粒细胞积聚。相比之下,在进食充足的清醒动物中,吸入变应原后仍会观察到早期呼吸道症状,但随后未出现明显的血液白细胞增多或肺中嗜酸性粒细胞积聚。通过组织学检查和组织过氧化物酶含量测定评估了禁食动物中变应原诱导的嗜酸性粒细胞流入,这两种测量方法显示出合理的一致性。在变应原激发前1小时给予单剂量的BW B70C(10 mg/kg口服)对24小时后随后的嗜酸性粒细胞浸润没有影响,但以分剂量(-1和+12小时)给予20 mg/kg可产生67%的细胞积聚抑制。单剂量50 mg/kg(-1小时)有类似效果(78%抑制)。强效糖皮质激素倍他米松用作参考化合物,以分剂量(-1和+7)给予4 mg/kg可完全抑制在变应原激发后24小时评估的肺部炎症。BW B70C抑制了豚鼠吸入变应原后的急性和过敏性支气管收缩以及后期嗜酸性粒细胞积聚。鉴于显然需要BW B70C的持续血浆水平以防止在单次变应原激发后后期嗜酸性粒细胞募集到肺中,尚不清楚5-脂氧合酶的抑制是否是该化合物观察到的抗嗜酸性粒细胞积聚作用的基础,但抗支气管收缩作用与BW B70C对5-脂氧合酶的已知抑制活性一致。